TY - JOUR T1 - The disease-induced herd immunity level for Covid-19 is substantially lower than the classical herd immunity level JF - medRxiv DO - 10.1101/2020.05.06.20093336 SP - 2020.05.06.20093336 AU - Tom Britton AU - Frank Ball AU - Pieter Trapman Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/14/2020.05.06.20093336.abstract N2 - Most countries are suffering severely from the ongoing covid-19 pandemic despite various levels of preventive measures. A common question is if and when a country or region will reach herd immunity h. The classical herd immunity level hC is defined as hC =1−1/R0, where R0 is the basic reproduction number, for covid-19 estimated to lie somewhere in the range 2.2-3.5 depending on country and region. It is shown here that the disease-induced herd immunity level hD, after an outbreak has taken place in a country/region with a set of preventive measures put in place, is actually substantially smaller than hC. As an illustration we show that if R0 =2.5 in an age-structured community with mixing rates fitted to social activity studies, and also categorizing individuals into three categories: low active, average active and high active, and where preventive measures affect all mixing rates proportionally, then the disease-induced herd immunity level is hD = 43% rather than hC =1−1/2.5 = 60%. Consequently, a lower fraction infected is required for herd immunity to appear. The underlying reason is that when immunity is induced by disease spreading, the proportion infected in groups with high contact rates is greater than that in groups with low contact rates. Consequently, disease-induced immunity is stronger than when immunity is uniformly distributed in the community as in the classical herd immunity level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementT.B. and P.T. acknowledge support from the Swedish Research CouncilAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript does not use any data ER -